Clinical trials: Carcinoma Liver
Hepatocellular Carcinoma
RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)
Hepatocellular carcinoma (HCC) is a common malignancy, and its incidence is expected to increase in many countries in coming decades. Approximately 70-80% of newly diagnosed HCC patients already have advanced disease.
- Trial name
- NCT04193696
- Testing
- Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Carcinoma, Hepatocellular
CT Imaging for Guiding PA-TACE for HCC
Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of…
- Trial name
- NCT06156748
- Testing
- postoperative adjuvant transarterial chemoembolization
- Where
- China
- Volunteers
- 1,770 people
- Sponsor
- Zhujiang Hospital
Liver Tumors, Hepatocellular Carcinoma
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
This is an interdisciplinary study that falls into the Humanitarian Use Device category. There are no hypotheses to be tested in this treatment protocol. The study has the following objectives: 1.
- Conditions
- Liver Tumors, Hepatocellular Carcinoma, Hepatoma, Neoplasms
- Trial name
- NCT00877136
- Testing
- TheraSphere®
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- St. Joseph Hospital of Orange
Antibiotic Prophylaxis
Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma
This study aims to determine the effectiveness of prophylactic antibiotic use for TACE and occurrence of postoperative liver abscess. There would be two comparison groups.
- Trial name
- NCT05654896
- Testing
- Ceftriaxone Sodium
- Where
- Pakistan
- Volunteers
- 158 people
- Sponsor
- Nadeem Iqbal
Advanced Hepatocellular Carcinoma
TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC
This trial is is an open label, multicenter, randomized controlled phase 3 clinical trial. The purpose is to compare the efficacy and safety of lenvatinib plus TACE with lenvatinib alone for advanced HCC patients.
- Trial name
- TACE (NCT03905967)
- Testing
- TACE, Lenvatinib
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms, Neuroendocrine Tumors
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
This is a prospective pilot study designed to document safety and efficacy of liver-directed therapy for colorectal, neuroendocrine, cholangiocarcinoma, melanoma, and breast cancer metastases to the liver using Yttrium-90 glass…
- Conditions
- Colorectal Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Melanoma
- Trial name
- NCT01290536
- Testing
- Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)
- Volunteers
- 42 people
- Sponsor
- Nicholas Fidelman, MD
Hepatocellular Carcinoma, Cirrhosis
LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
The purpose of this study is to test the safety and determine the maximum safe dose of an experimental drug called LDE225 (hedgehog inhibitor) in people with liver cancer.
- Trial name
- NCT02151864
- Testing
- LDE225
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jason K. Sicklick, M.D.
HCC - Hepatocellular Carcinoma
Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
This study aims to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (the combination antibody) combined with SBRT and Lenvatinib in the perioperative treatment of patients with potentially resectable…
- Trial name
- NCT07801287
- Testing
- Iparomlimab/Tuvonralimab plus SBRT and Lenvatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC)
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors
- Conditions
- Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC), Head and Neck Cancer Squamous Cell Carcinoma, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- NCT07390838
- Testing
- SH009
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
TACE, HCC - Hepatocellular Carcinoma
Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407)
Liver abscess is a rare but serious complication of hepatocellular carcinoma after TACE, with an incidence of less than 1% reported in previous literature.
- Conditions
- TACE, HCC - Hepatocellular Carcinoma, Liver Abscess
- Trial name
- NCT06483594
- Volunteers
- 400 people
- Sponsor
- Shengjing Hospital
Carcinoma, Hepatocellular
Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer
The purpose of this study is to assess the safety and tolerability of foretinib (also known as GSK1363089) when used in the treatment of patients with advanced hepatocellular carcinoma (liver cancer).
- Trial name
- NCT00920192
- Testing
- Foretinib
- Where
- 7 sites in Hong Kong, Taiwan and 1 more
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Hepatocellular Carcinoma
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
An open-label multi-center phase II study to evaluate the efficacy and safety of anti-PD-1/CTLA-4 bispecific antibody AK104 alone or in combination with lenvatinib in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT04728321
- Testing
- AK104 lenvatinib, AK104
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Akeso
Cancer of Liver
Impact of Gender on the Outcome of Liver Transplantation for Hepatocellular Carcinoma
This is a large-scale study in China to provide evidence and insights in the role of gender in LT for HCC by analyzing the data of 3769 recipients with HCC registered in the China Liver Transplant Registry.
- Trial name
- NCT05643833
- Testing
- no intervention
- Where
- China
- Volunteers
- 3,769 people
- Sponsor
- Zhejiang University
Cancer Liver, Cancer Head Neck
PREoPerAtive pREhabilitation in Patients With Head and Neck Cancer or Liver Cancer (PREPARE)
The objective of this study is to determine the feasibility (main aim) and effectiveness (secondary aim) of a prehabilitation program in patients with head and neck cancer or liver cancer.
- Trial name
- PREPARE (NCT05745558)
- Testing
- Prehabilitation
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Erasmus Medical Center
Hepatocellular Carcinoma
Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma
The aim of this study is to explore the effect of S-Adenosyl Methionine on recurrence after curative resection of Hepatocellular Carcinoma.
- Trial name
- NCT02586285
- Testing
- S-Adenosyl Methionine
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with hepatocellular carcinoma who have failed prior systemic treatment (chemotherapy).
- Trial name
- ADI-PEG 20 (NCT01287585)
- Testing
- ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol), Best Supportive Care
- Where
- 73 sites in United States, China and 4 more
- Volunteers
- 636 people
- Sponsor
- Polaris Group
HCC
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
Major objectives To evaluate the efficacy of lparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1/ CTLA-4 Combined Antibody) in combination with TACE and lenvatinib as second-line therapy in patients with unresectable…
- Trial name
- NCT07099274
- Testing
- lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
This registry seeks to prospectively gather a large repository of comprehensive observational data reflecting routine use of SIR-Spheres in patients diagnosed with unresectable HCC or unresectable liver metastases from mCRC…
- Trial name
- SIRtain (NCT05967143)
- Testing
- SIRT
- Where
- 9 sites in France, Spain and 1 more
- Volunteers
- 845 people
- Sponsor
- Sirtex Medical
Hepatocellular Carcinoma (HCC), Cirrhosis
mSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis
This study aims to evaluate the role of the circulating epigenetic biomarker mSEPT9 in predicting the risk of hepatocellular carcinoma (HCC) in patients with cirrhosis.
- Conditions
- Hepatocellular Carcinoma (HCC), Cirrhosis, Risk Prediction for Liver Cancer, Epigenomics
- Trial name
- SEPT9_SuRV (NCT06778317)
- Testing
- Circulating mSEPT9 Biomarker Testing
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Central Hospital, Nancy, France